Streetbeat News

Regulatory

LLY

Eli Lilly announced that its SURMOUNT-2 study results published in The Lancet show tirzepatide achieved a mean weight reduction of 15.7% at the highest dose (15 mg) in adults with obesity or overweight and type 2 diabetes.

Portfolio Pulse from Charles Gross

June 26, 2023 | 11:49 am

AVTX

Avalo announced positive topline data from its Phase 2 PEAK trial for AVTX-002 in patients with non-eosinophilic asthma, indicating potential for the drug's future development.

Portfolio Pulse from Benzinga Newsdesk

June 26, 2023 | 11:38 am

ADMP

Adamis Pharmaceuticals has received an undisclosed amount of grant funding from the National Institutes of Health (NIH) for the development of a treatment for alcohol use disorder.

Portfolio Pulse from Bill Haddad

June 26, 2023 | 11:37 am

OPGN

SYNH

OpGen's subsidiary Ares Genetics has maintained its patent titled 'Genetic Resistance Prediction Against Antimicrobial Drugs In Microorganism Using Structural Changes In The Genome' in Europe.

Portfolio Pulse from Bill Haddad

June 26, 2023 | 11:37 am

FGEN

FibroGen announced positive topline results from its Phase 3 ZEPHYRUS-1 study of Pamrevlumab for the treatment of idiopathic pulmonary fibrosis.

Portfolio Pulse from Benzinga Newsdesk

June 26, 2023 | 11:36 am

FGEN

FibroGen shares resumed trading and are down 74.3% after a halt due to concerns over the company's anemia drug.

Portfolio Pulse from Bill Haddad

June 26, 2023 | 11:33 am

ALXO

The European Commission has granted Orphan Drug Designation to ALX Oncology's Evorpacept for the treatment of gastric cancer, including gastric cancer and gastroesophageal junction adenocarcinoma.

Portfolio Pulse from Benzinga Newsdesk

June 26, 2023 | 11:05 am

PFE

Pfizer has decided to terminate the clinical development of its obesity drug Lotiglipron, potentially impacting the company's future product pipeline.

Portfolio Pulse from Charles Gross

June 26, 2023 | 11:03 am

AVTX

Avalo Therapeutics' shares have been halted due to pending news.

Portfolio Pulse from Charles Gross

June 26, 2023 | 10:57 am

PFE

Pfizer is advancing its oral GLP-1-RA candidate danuglipron towards late-stage development for the treatment of obesity and type 2 diabetes mellitus (T2DM). The ongoing Phase 2b study in obesity is fully enrolled, with over 1,400 participants. Pfizer will discontinue its second GLP-1-RA candidate, lotiglipron.

Portfolio Pulse from Benzinga Newsdesk

June 26, 2023 | 10:53 am